Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Joly

Showing results (131-140 of 227) with videos related to

Pageof 23
Sort By:
Archives of Dermatology|January 21, 2009
Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failureMajed Eshki, Laurence Allanore, Philippe Musette, et al.
Nature Reviews. Disease Primers|February 20, 2025
Bullous pemphigoidHossein Akbarialiabad, Enno Schmidt, Aikaterini Patsatsi, et al.
The Journal of Investigative Dermatology|June 20, 2008
B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responsesHugo Mouquet, Philippe Musette, Marie-Lyse Gougeon, et al.
Advances in Therapy|March 5, 2024
Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPTDédée F Murrell, Pascal Joly, Victoria P Werth, et al.
Nature Reviews. Disease Primers|March 3, 2025
Author Correction: Bullous pemphigoidHossein Akbarialiabad, Enno Schmidt, Aikaterini Patsatsi, et al.
The Journal of Investigative Dermatology|June 18, 2026
Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigusMaud Maho-Vaillant, Alexis Lefebvre, Marie-Laure Golinski, et al.
Advances in Therapy|May 24, 2024
Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPTDédée F Murrell, Pascal Joly, Victoria P Werth, et al.
The Journal of Investigative Dermatology|March 17, 2024
Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized StudyDedee F Murrell, Frédéric Caux, Aikaterini Patsatsi, et al.
The British Journal of Dermatology|November 25, 2025
Bullous Pemphigoid Outcome Measurement: A Scoping Review of Outcome Heterogeneity and Trends in Clinical Research of TreatmentsMarjolein A J Hiel, Billal Tedbirt, Eva W H Korte, et al.
Clinical Drug Investigation|September 23, 2025
Mucous Membrane Pemphigoid Outcome Measurement in Clinical Research: A Scoping ReviewBillal Tedbirt, Eva W H Korte, Marjolein A J Hiel, et al.
Pageof 23

Showing results (131-140 of 227) with videos related to

Sort By:
Pageof 23
Archives of Dermatology|January 21, 2009
Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failureMajed Eshki, Laurence Allanore, Philippe Musette, et al.
Nature Reviews. Disease Primers|February 20, 2025
Bullous pemphigoidHossein Akbarialiabad, Enno Schmidt, Aikaterini Patsatsi, et al.
The Journal of Investigative Dermatology|June 20, 2008
B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responsesHugo Mouquet, Philippe Musette, Marie-Lyse Gougeon, et al.
Advances in Therapy|March 5, 2024
Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPTDédée F Murrell, Pascal Joly, Victoria P Werth, et al.
Nature Reviews. Disease Primers|March 3, 2025
Author Correction: Bullous pemphigoidHossein Akbarialiabad, Enno Schmidt, Aikaterini Patsatsi, et al.
The Journal of Investigative Dermatology|June 18, 2026
Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigusMaud Maho-Vaillant, Alexis Lefebvre, Marie-Laure Golinski, et al.
Advances in Therapy|May 24, 2024
Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPTDédée F Murrell, Pascal Joly, Victoria P Werth, et al.
The Journal of Investigative Dermatology|March 17, 2024
Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized StudyDedee F Murrell, Frédéric Caux, Aikaterini Patsatsi, et al.
The British Journal of Dermatology|November 25, 2025
Bullous Pemphigoid Outcome Measurement: A Scoping Review of Outcome Heterogeneity and Trends in Clinical Research of TreatmentsMarjolein A J Hiel, Billal Tedbirt, Eva W H Korte, et al.
Clinical Drug Investigation|September 23, 2025
Mucous Membrane Pemphigoid Outcome Measurement in Clinical Research: A Scoping ReviewBillal Tedbirt, Eva W H Korte, Marjolein A J Hiel, et al.
Pageof 23